Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Elicio Therapeutics (ELTX)

Elicio Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ELTX
DateTimeSourceHeadlineSymbolCompany
28/06/202414:00GlobeNewswire Inc.Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public OfferingNASDAQ:ELTXElicio Therapeutics Inc
27/06/202421:05GlobeNewswire Inc.Elicio Therapeutics Announces Proposed Public OfferingNASDAQ:ELTXElicio Therapeutics Inc
27/06/202421:01GlobeNewswire Inc.Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7PNASDAQ:ELTXElicio Therapeutics Inc
18/06/202413:30GlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
12/06/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
12/06/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
03/06/202422:24Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELTXElicio Therapeutics Inc
03/06/202421:41Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ELTXElicio Therapeutics Inc
23/05/202422:30GlobeNewswire Inc.Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
15/05/202421:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
15/05/202421:30GlobeNewswire Inc.Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
25/04/202413:30GlobeNewswire Inc.Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
05/04/202421:30GlobeNewswire Inc.Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
29/03/202412:30GlobeNewswire Inc.Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
18/03/202412:00GlobeNewswire Inc.Elicio Therapeutics Announces $6.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
05/02/202413:30GlobeNewswire Inc.Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ELTXElicio Therapeutics Inc
25/01/202414:00GlobeNewswire Inc.Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid TumorsNASDAQ:ELTXElicio Therapeutics Inc
17/01/202413:30GlobeNewswire Inc.Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI SymposiumNASDAQ:ELTXElicio Therapeutics Inc
16/01/202413:30GlobeNewswire Inc.Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:ELTXElicio Therapeutics Inc
11/01/202413:30GlobeNewswire Inc.Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer StudyNASDAQ:ELTXElicio Therapeutics Inc
09/01/202411:00GlobeNewswire Inc.Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002NASDAQ:ELTXElicio Therapeutics Inc
22/12/202314:00GlobeNewswire Inc.Elicio Therapeutics Announces $7.0 Million Private Placement FinancingNASDAQ:ELTXElicio Therapeutics Inc
04/12/202313:00GlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:ELTXElicio Therapeutics Inc
09/11/202321:30GlobeNewswire Inc.Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
03/11/202320:30GlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
11/10/202313:00GlobeNewswire Inc.Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
27/09/202322:30GlobeNewswire Inc.Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
07/09/202313:00GlobeNewswire Inc.Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer VaccinesNASDAQ:ELTXElicio Therapeutics Inc
06/09/202313:00GlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ELTXElicio Therapeutics Inc
05/09/202313:00GlobeNewswire Inc.Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic CancerNASDAQ:ELTXElicio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ELTX